Sector: Health Care
Director information for APELLIS PHARMACEUTICALS INC (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alec Machiels | Independent Director | 52 | ["Founding Managing Partner, CoLift, LLC", "Partner, Pegasus Capital Advisors", "Co-Founder and CEO of Potentia Pharmaceuticals", "Strong background in financial management and investment"] | ["Audit (Chair)", "Compensation", "Compliance"] | 2025 |
| A. Sinclair Dunlop | Independent Director | 53 | ["Co-Founder and Managing Partner, Epidarex Capital", "Founder and Managing Partner, Masa Life Science Ventures", "Extensive investment and business experience", "20 years of experience in early-stage life science companies"] | ["Audit", "Nominating and Corporate Governance"] | 2025 |
| Caroline Baumal, M.D. | Chief Medical Officer | 58 | ["Chief Medical Officer (January 2023 \u2013 present)", "Professor of Ophthalmology, Vitreoretinal surgeon, New England Eye Center/Tufts Medicine (1998 \u2013 present)", "Key opinion leader in ophthalmology, retinal imaging and therapeutics, ophthalmic devices and drug delivery", "Clinical research principal investigator and DSMC member for numerous clinical studies"] | [] | 2025 |
| Cedric Francois, M.D., Ph.D. | President and Chief Executive Officer | 52 | ["Co-Founder, President and Chief Executive Officer, Apellis (2009 \u2013 present)", "Co-Founder, President and Chief Executive Officer, Potentia Pharmaceuticals, Inc. (private, 2001 \u2013 2018)", "Co-Founder, Revon Systems, LLC (Revon), a private healthcare software company (2014 \u2013 2019)", "Member of the research team that performed the first successful hand transplantation", "Member of the Louisville Face Transplant Team"] | [] | 2025 |
| Craig Wheeler | 63 | ["CEO of Headwaters Biotech Advisors (2020 \u2013 present)", "President and Chief Executive Officer of Momenta Pharmaceuticals (2006 \u2013 2020)", "President of Chiron Biopharmaceuticals (2001 \u2013 2006)", "Senior member of The Boston Consulting Group\u2019s health care practice", "Expertise and extensive leadership experience in pharmaceutical industry", "Expertise in drug development, manufacturing, and the technical issues facing growing biopharmaceutical companies"] | ["Audit"] | 2025 | |
| Gerald Chan, Sc.D. | Chairman of the Board | 74 | ["Co-Founder, Morningside Group, a private investment group with venture, private equity and property investments (1986 \u2013 present)", "Member, American Academy of Arts and Sciences (since 2017)", "Member, Scientific Advisory Committee of Brigham and Women\u2019s Hospital (since 2018)", "Member, Global Advisory Council of Harvard University (since 2012)", "Member, Dean\u2019s Board of Advisors of the Harvard T.H. Chan School of Public Health (since 2011)", "Chair of the Innovation Advisory Committee of the Wellcome Trust (2016-2020)", "Trustee, Scripps Research Institute (since 2017)", "Extensive experience in life science investments and serving on boards of directors of technology and biotechnology companies"] | ["Nominating and Corporate Governance"] | 2025 |
| Keli Walbert | Independent Director | 58 | ["Executive Vice President, US Commercial, Horizon Therapeutics", "Executive roles with AbbVie Pharmaceuticals", "Expertise in biotech/pharma sales and commercial strategy"] | ["Compensation", "Compliance", "Nominating & Corporate Governance"] | 2025 |
| Mark DeLong | Chief Business & Strategy Officer | 48 | ["Chief Business & Strategy Officer (January 2023 \u2013 present)", "Senior Vice President, Business Development & Strategy (February 2020 \u2013 January 2023)", "Various leadership roles at EMD Serono, including Head of Global Portfolio Management, Neurology & Immunology Franchise", "Managing Director, Bluepoint Healthcare Consulting, LLC"] | [] | 2025 |
| Nur Nicholson | Chief Technical Operations Officer | 56 | ["Experience as Chief Technical Operations Officer since August 2020", "Vice President of North American Business Operations and Intelligence and Head of Global Supply Chain at Galderma", "Head of Global Supply Chain for the Pharmaceutical Franchise at Alcon", "Roles in clinical and regulatory affairs operations, clinical infometrics, resource management and sales operations", "B.S. in Chemistry from Middle East Technical University", "Executive M.B.A. from M.J. Neely School of Business at Texas Christian University"] | [] | 2025 |
| Pascal Deschatelets, Ph.D. | Co-Founder and Chief Scientific Officer | 55 | ["Co-Founder, Chief Scientific Officer (July 2020 \u2013 present)", "Co-Founder, Chief Operating Officer (2009 \u2013 July 2020)", "Co-Founder and Chief Operating Officer, Potentia (2001 \u2013 September 2016)", "Co-Founder, Revon (2013 \u2013 2019)"] | [] | 2025 |
| Paul Fonteyne | Independent Director | 63 | ["Executive-in-Residence, Canaan Partners, a venture capital firm dedicated to early stage investing in health care and technology (2019 \u2013 present)", "Held number of senior executive roles, Boehringer Ingelheim", "Chairman, Boehringer Ingelheim USA (2018 \u2013 2019)", "President and Chief Executive Officer, Boehringer Ingelheim USA (2011 \u2013 2018)", "President, Boehringer Ingelheim Animal Health USA (2018 \u2013 2019)", "Corporate Senior Vice President, Prescription Medicines Marketing, Boehringer Ingelheim GmbH (2009 \u2013 2011)", "Joined 2004", "Held commercial leadership roles, Merck and Co. Inc. (1995 \u2013 2004)", "Held commercial leadership roles, Abbott Laboratories (1987 \u2013 1995)"] | ["Audit", "Compensation", "Compliance"] | 2025 |
| Stephanie Monaghan O’Brien | Independent Director | 66 | ["Attorney, Morningside Technology Advisory, LLC (1997 \u2013 present)"] | ["Compensation", "Nominating and Corporate Governance", "Compliance"] | 2025 |
